Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 0.61 |
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.55 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11741196 | 1.00 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL9188152 | 0.98 | GAA (0.58) | GAARAB9ATDP1MAPTNPC1 | |
| SCHEMBL6710 | 0.97 | GAA (0.64) | GAARAB9ATDP1MAPTNPC1 | |
| SCHEMBL28983971 | 0.95 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 | |
| Bromide SCHEMBL20984524 | 0.95 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 | |
| SCHEMBL29896240 | 0.95 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 | |
| SCHEMBL8863654 | 0.95 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 | |
| Methane SCHEMBL9779840 | 0.95 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 | |
| Water SCHEMBL721160 | 0.95 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 | |
| Phosphine SCHEMBL8863649 | 0.95 | GAA (0.61) | GAARAB9ATDP1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119505155-A | Method for preparing photosensitive polyion liquid photoelectric device by dispensing | 四川大学 | 2025-02-25 | — | — | CN | claimed |
| CN-119431182-A | Preparation method of 4-methoxy phenylhydrazine hydrochloride | 安徽昊帆生物有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | claimed |
| CN-119330873-A | In itramod Process for the preparation of intermediates | 成都克莱蒙医药科技有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-116375703-B | Synthesis process of apixaban | 常州制药厂有限公司 | 2025-01-17 | — | — | CN | claimed |
| CN-114230507-B | Preparation method of 5-methoxy tryptamine | 阜阳欣奕华制药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-114989066-B | Preparation method of indomethacin | 暨明医药科技（苏州）有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116887609-A | Perovskite thin film layer and preparation method thereof, perovskite silicon laminated solar cell and preparation method thereof | 通威太阳能（成都）有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-112341357-B | Preparation method of 4-methoxy phenylhydrazine hydrochloride | 国药集团化学试剂有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-116375703-A | Synthesis process of apixaban | 常州制药厂有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-110204541-A | A kind of preparation method of Eliquis | 新发药业有限公司 | 2019-09-06 | — | — | CN | claimed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | claimed |
| CN-108558732-A | A kind of indole amides class compound of alternative treatment gastric cancer and cervical carcinoma | 南华大学 | 2018-09-21 | — | — | CN | claimed |
| CN-106243010-A | A kind of preparation method of 4 nitroindolines | 叶芳 | 2016-12-21 | — | — | CN | claimed |
| CN-101935331-B | Novel 4,5-pyrazoline ring-containing helicid medicament with sedative activity and preparation method thereof | UNIV SICHUAN | 2013-04-24 | — | — | CN | claimed |
| EP-2285803-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | Amira Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2010068311-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| WO-1999006399-A1 | ARYL-SUBSTITUTED PYRAZOLOQUINOLINONE DERIVATIVES AS GABA ALPHA 5 RECEPTOR INVERSE AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-11 | — | — | WO | claimed |
| US-5380869-A | Regioselective synthesis of 1,5-diaryl pyrazole anti-inflammatory agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-01-10 | — | — | US | claimed |
| EP-0534800-A2 | Regioselective synthesis of 1,5-diaryl pyrazole anti-inflammatory agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-03-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | HPD, TYR, PDK2 | GAA 237/4885CA2 931/4885ACHE 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.